Overactive bladder is a symptom syndrome characterized by urinary urgency, often with frequency and nocturia, with or without urge incontinence, due to abnormal bladder storage function.
Astellas Pharma reported fiscal 2026 sales of ¥2.14 trillion and net income of ¥291.54 billion, alongside an FDA Priority Review for PADCEV plus Keytruda in muscle-invasive bladder cancer. The company also settled U.S. Myrbetriq patent disputes with Lupin and Zydus. Shares trade at ¥2,470 with mixed valuation signals.
Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07716774 |
SGLT-2 Inhibitors and Lower Urinary Tract Symptoms |
ACTIVE_NOT_RECRUITING | |
| NCT07693192 |
Comparative Efficacy and Safety if Intravesical Botulinum Toxin A Versus Platelet-Rich Plasma in the Management of Refractory Overactive Bladder : A 2 Year Study |
ACTIVE_NOT_RECRUITING | NA |
| NCT07662824 |
Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy |
NOT_YET_RECRUITING | NA |
| NCT07648290 |
Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms |
RECRUITING | EARLY_PHASE1 |
| NCT07513363 |
The Role of Urinary RhoA, NGF, and BDNF Levels in Overactive Bladder and Vitamin D Deficiency |
NOT_YET_RECRUITING | NA |
| NCT07463326 |
The Efficacy of Transcutaneous Tibial Nerve Stimulation in Women With Idiopathic Overactive Bladder |
ENROLLING_BY_INVITATION | NA |
| NCT07452796 |
Turkish USIQ: Validity & Reliability |
NOT_YET_RECRUITING | |
| NCT07432659 |
Add-On ZIDA Sock Therapy for Overactive Bladder |
RECRUITING | NA |
| NCT07429734 |
Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women |
NOT_YET_RECRUITING | PHASE3 |
| NCT07387315 |
A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections |
NOT_YET_RECRUITING | PHASE4 |
